Ernexa Therapeutics Inc. ERNA

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing nov

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy Biodistribution study showed no significant ERNA-101 signal in tumor-free